Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, June 1, 2023
Information
Tags: 
Biotechnology, Health, Oncology, Cancer, Conference, ACET, Bio, Pharmaceutical industry
Geotags: 
UNITED STATES, NORTH AMERICA, MASSACHUSETTS, CALIFORNIA, NEW YORK
⚠ partially generated by AI ↴
Organisation: 
ADICET BIO, ADICET BIO, INC.
Stock Symbol: 
NASDAQ:ACET
Summary
Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.
  • Details of the event are as follows:
    The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com .
  • An archived replay will be available for 30 days following the presentation.


Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.

Details of the event are as follows:

Date: Thursday, June 8, 2023

Time: 10:30 a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Copyright: 
Copyright Business Wire 2023